Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherRadionuclide Therapy (JNMT)

Review of Palliative Radium 223 (223Ra) in metastatic castration resistant prostate cancer (mCRPC): Experience at West Virginia University (WVU) Cancer Center

Ruta Arays, Zeeshan Ahmad, Lorinda Howard, Kenneth Veselicky, Joanna Kolodney and Thomas Hogan
Journal of Nuclear Medicine Technology November 2020, jnmt.120.254474; DOI: https://doi.org/10.2967/jnmt.120.254474
Ruta Arays
West Virginia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeeshan Ahmad
West Virginia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorinda Howard
West Virginia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Veselicky
West Virginia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Kolodney
West Virginia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Hogan
West Virginia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

BACKGROUND: The ALSYMPCA trial of α-emitter Ra-223 in symptomatic bone predominant mCRPC reported Ra-223 median overall survival (OS) of 14.9 months versus 11.3 months OS for placebo (1). Subsequently reported “real world” experience with Ra-223 in smaller mCRPC patient cohorts appeared less successful(2-3). We decided to review our own Ra-223 experience at WVU. PATIENTS: Demographic, clinical and laboratory data, and all available images were reviewed in bone predominant mCRPC treated with Ra-223 at WVU. The number of bone metastases per patient as quantified. Standard descriptive statistics were used to study IRB-exempt, de-identified patient data. The primary end-point was patient overall survival (OS) after initiating Ra-223. RESULTS: Twenty four men received 98 infusions of Ra-223; 83%of these men were referred from outside WVU. Prior to first infusion, all 24 had received a total of 73 sequential combinations of androgen deprivation therapy (ADT); 68 courses of ADT (93%) preceded the first Ra-223 infusion. Before Ra-223, 19(79%) received docetaxel and 19 (79%) received 33 courses of radiation --24 courses targeting non-prostate sites. Eleven men (46%) completed all six planned Ra-223 infusions; 13 (54%) stopped early for clinical deterioration or death. Median OS from first Ra-223 infusion to last follow-up or death was 8.3 months (range 0-44 mos.) -- nearly 50% less than the ALSYMPCA results. Compared to ALSYMPCA, more WVU patients had received bisphosphonates and docetaxel, more had ECOG PS >2, more used opiates for pain, more had greater bone metastases burden, and more had lower hemoglobin, albumin, alkaline phosphatase, and PSA levels. CONCLUSION: While the science supporting the development and clinical use of Ra-223 is compelling, optimal clinical benefit will likely require earlier referral for Ra-223, before patients have exhausted most conventional therapies. At WVU, we found that our referred patients had practically all ADT, radiation, and cytotoxic therapy before starting Ra-223. A 2019 report from McMaster University using Ra-223 in 60 men with heavily pre-treated mCRPC also found a median OS of 8.2 months with only 42% completing all six treatment cycles, results almost identical to ours(2). Other studies confirmed that men with less advanced mCRPC, receiving the full course of Ra-223, had better OS(3). Now, we offer Ra-223 to men with symptomatic bone-predominant CRPC but we highly encourage earlier referral.

  • Genitourinary
  • Oncology: GU
  • Radionuclide Therapy
  • Castration Resistant Prostate Cancer
  • Metastatic Prostate Cancer
  • Prostate Cancer Metastatic to bone

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 49 (1)
Journal of Nuclear Medicine Technology
Vol. 49, Issue 1
March 1, 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Review of Palliative Radium 223 (223Ra) in metastatic castration resistant prostate cancer (mCRPC): Experience at West Virginia University (WVU) Cancer Center
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Review of Palliative Radium 223 (223Ra) in metastatic castration resistant prostate cancer (mCRPC): Experience at West Virginia University (WVU) Cancer Center
Ruta Arays, Zeeshan Ahmad, Lorinda Howard, Kenneth Veselicky, Joanna Kolodney, Thomas Hogan
Journal of Nuclear Medicine Technology Nov 2020, jnmt.120.254474; DOI: 10.2967/jnmt.120.254474

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Review of Palliative Radium 223 (223Ra) in metastatic castration resistant prostate cancer (mCRPC): Experience at West Virginia University (WVU) Cancer Center
Ruta Arays, Zeeshan Ahmad, Lorinda Howard, Kenneth Veselicky, Joanna Kolodney, Thomas Hogan
Journal of Nuclear Medicine Technology Nov 2020, jnmt.120.254474; DOI: 10.2967/jnmt.120.254474
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Keywords

  • Genitourinary
  • Oncology: GU
  • Radionuclide Therapy
  • Castration Resistant Prostate Cancer
  • Metastatic Prostate Cancer
  • Prostate Cancer Metastatic to bone
SNMMI

© 2021 Journal of Nuclear Medicine Technology

Powered by HighWire